Journal Articles
Research publications from the Lipodystrophy research community
Tirzepatide for Congenital Generalized Lipodystrophy
Tirzepatide use in CGL shows potential metabolic benefit.. . .
The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
Early findings from the LD Lync registry reveal a substantial disease burden across 61 individuals. Delays in diagnosis averaged 14 years, and the majority of participants had serious metabolic compli. . .
Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
This study found that over 70% of people with lipodystrophy experience pain, with more than half reporting moderate to severe pain. This pain was strongly associated with poorer quality of life, great. . .
Oral Glucagon-Like Peptide 1 Analog as an Adjuvant Therapy in Generalized Lipodystrophy
A new case study co-authored by Lipodystrophy United’s Scientific Director, Sharon Halperin, highlights the first successful use of an oral GLP-1 medication (semaglutide) in a patient with generalize. . .
Lipodystrophy Severity Score to Assess Disease Burden in Lipodystrophy
Developed a standardized severity score for lipodystrophy burden assessment. The LDS had high content validity and feasibility and high reliability by intraclass correlation coefficients (>0.95). Side. . .
Impact of lipodystrophy on health-related quality of life
Over a 24-month period, 27.69% of adult patients were diagnosed with various psychiatric disorders, such as depressive episodes, anxiety disorders, and adjustment disorders, highlighting underdiagnosi. . .
Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy
The study introduces a diagnostic method called "fat shadows" derived from DXA scans to identify lipodystrophy syndromes.. . .
Experiences and Perspectives of Patients with Non-HIV-Associated Lipodystrophies and Their Caregivers: A Qualitative Study
This qualitative study identified four key themes in the experiences of people with lipodystrophy and their caregivers: the diagnostic journey and symptom management, burden of disease, healthcare sys. . .
Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients with Familial Partial Lipodystrophy
In a clinical trial involving patients with familial partial lipodystrophy type 2 (FPLD2), obeticholic acid (OCA) therapy significantly reduced liver fat by 39.6% compared to placebo. While no signifi. . .
Congenital generalised lipodystrophy type 2
Detailed clinical presentation of a patient with CGL type 2.. . .